Regeneron - Pharma Company Impresses with a Strong Outlook Thanks to Dupixient and Eylea!
Reading Time: 1 minute
Business drivers: Regeneron Pharmaceuticals (REGN ) specializes in the development of new drugs and therapies for rare diseases and collaborates with numerous heavyweights from the pharmaceutical and biotech industries such as Sanofi and Bayer. In this context, Regeneron has secured the marketing rights for the eye medication Eylea as well as the drug Dupixient, which is approved for the treatment of asthma and atopic dermatitis. Since Dupixient received an expanded indication approval from the FDA for the treatment of chronic obstructive pulmonary...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
